Dr. Lal PathLabs Dividends and Buybacks
Dividend criteria checks 3/6
Dr. Lal PathLabs is a dividend paying company with a current yield of 0.61% that is well covered by earnings.
Key information
0.6%
Dividend yield
-0.03%
Buyback Yield
| Total Shareholder Yield | 0.6% |
| Future Dividend Yield | 1.0% |
| Dividend Growth | 9.0% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | ₹18.000 |
| Payout ratio | 62% |
Recent dividend and buyback updates
Recent updates
Analysts Are Updating Their Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Estimates After Its Second-Quarter Results
Oct 26
Capital Investment Trends At Dr. Lal PathLabs (NSE:LALPATHLAB) Look Strong
Oct 24Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Share Price Could Signal Some Risk
Oct 06These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Jul 28We Think Dr. Lal PathLabs' (NSE:LALPATHLAB) Profit Is Only A Baseline For What They Can Achieve
May 21What Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) P/E Is Not Telling You
May 01Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Apr 13These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Safely
Mar 06Dr. Lal PathLabs Limited Just Missed EPS By 5.4%: Here's What Analysts Think Will Happen Next
Feb 04Subdued Growth No Barrier To Dr. Lal PathLabs Limited's (NSE:LALPATHLAB) Price
Dec 28Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Nov 17Dr. Lal PathLabs (NSE:LALPATHLAB) Will Be Hoping To Turn Its Returns On Capital Around
Oct 12Here's Why Dr. Lal PathLabs (NSE:LALPATHLAB) Can Manage Its Debt Responsibly
Jul 07Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 10Dr. Lal PathLabs (NSE:LALPATHLAB) Could Be Struggling To Allocate Capital
Feb 13Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?
Dec 29Dr. Lal PathLabs (NSE:LALPATHLAB) Will Want To Turn Around Its Return Trends
Sep 21These 4 Measures Indicate That Dr. Lal PathLabs (NSE:LALPATHLAB) Is Using Debt Reasonably Well
Sep 01Dr. Lal PathLabs (NSE:LALPATHLAB) Will Pay A Dividend Of ₹6.00
Jul 31Be Wary Of Dr. Lal PathLabs (NSE:LALPATHLAB) And Its Returns On Capital
Jun 23Does This Valuation Of Dr. Lal PathLabs Limited (NSE:LALPATHLAB) Imply Investors Are Overpaying?
Jun 11Stability and Growth of Payments
Fetching dividends data
Stable Dividend: LALPATHLAB has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: LALPATHLAB's dividend payments have increased, but the company has only paid a dividend for 9 years.
Dividend Yield vs Market
| Dr. Lal PathLabs Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (LALPATHLAB) | 0.6% |
| Market Bottom 25% (IN) | 0.2% |
| Market Top 25% (IN) | 1.1% |
| Industry Average (Healthcare) | 0.3% |
| Analyst forecast (LALPATHLAB) (up to 3 years) | 1.0% |
Notable Dividend: LALPATHLAB's dividend (0.61%) is higher than the bottom 25% of dividend payers in the Indian market (0.24%).
High Dividend: LALPATHLAB's dividend (0.61%) is low compared to the top 25% of dividend payers in the Indian market (1.1%).
Earnings Payout to Shareholders
Earnings Coverage: With its reasonable payout ratio (62.2%), LALPATHLAB's dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its reasonably low cash payout ratio (30.5%), LALPATHLAB's dividend payments are well covered by cash flows.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 23:21 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Dr. Lal PathLabs Limited is covered by 44 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Prashant Nair | Ambit Capital |
| null null | Antique Stockbroking Ltd. |
| Harith Ahamed | Avendus Spark |